Literature DB >> 14648148

Diagnosis of Lyme neuroborreliosis with antibodies to recombinant proteins DbpA, BBK32, and OspC, and VlsE IR6 peptide.

Jaana Panelius1, Pekka Lahdenne, Harri Saxén, Sten-Anders Carlsson, Tero Heikkilä, Miikka Peltomaa, Anneli Lauhio, Ilkka Seppälä.   

Abstract

Three recombinant antigens, decorin binding protein A (DbpA), BBK32, and outer surface protein C (OspC), and IR(6) peptide of borrelial VlsE protein, were evaluated for the diagnosis of neuroborreliosis (NB), using cerebrospinal fluid (CSF) and serum samples from 89 patients. Their performances in enzyme-linked immunosorbent assay (ELISA) were compared with that of commercial flagella antigen. IgG ELISAs were performed with three variants of each recombinant antigen originating from Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii, and with the IR(6) peptide. IgM antibodies were analysed against OspC and flagella. Of the patients whose CSF contained elevated anti-flagella IgG antibodies, 93% were positive for at least three of the new antigens. Of those with negative or borderline CSF anti-flagella antibodies, 51% were positive for three new antigens. Antibodies to BBK32 were detectable mainly in early disease. Antibodies to DbpA and IR(6) were observed in early and late NB. The use of the new antigens at presentation of the disease improved the laboratory diagnosis of NB. In IgG ELISAs, the diagnostic sensitivity of assays with the new antigens was between 75 and 88%, but was only 52% with the flagella antigen. The discriminatory power between patient and control samples appeared better in the CSF than in the serum. We suggest that assessment of CSF antibodies to at least two antigens, using either flagella and one of the new antigens or two of the new antigens, would improve the current diagnostic yield of NB.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14648148     DOI: 10.1007/s00415-003-0205-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  14 in total

1.  A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis.

Authors:  Mario T Philipp; Gary P Wormser; Adriana R Marques; Susan Bittker; Dale S Martin; John Nowakowski; Leonard G Dally
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

2.  Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues.

Authors:  Gereon Goettner; Ulrike Schulte-Spechtel; Ruth Hillermann; Gabi Liegl; Bettina Wilske; Volker Fingerle
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  Serologic evaluation of patients from Missouri with erythema migrans-like skin lesions with the C6 Lyme test.

Authors:  Mario T Philipp; Edwin Masters; Gary P Wormser; Wayne Hogrefe; Dale Martin
Journal:  Clin Vaccine Immunol       Date:  2006-10

4.  Dynamic longitudinal antibody responses during Borrelia burgdorferi infection and antibiotic treatment of rhesus macaques.

Authors:  Monica E Embers; Nicole R Hasenkampf; Mary B Jacobs; Mario T Philipp
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

5.  Effects of vlsE complementation on the infectivity of Borrelia burgdorferi lacking the linear plasmid lp28-1.

Authors:  Matthew B Lawrenz; R Mark Wooten; Steven J Norris
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Borrelia burgdorferi spirochetes that harbor only a portion of the lp28-1 plasmid elicit antibody responses detectable with the C6 test for Lyme disease.

Authors:  Monica E Embers; Gary P Wormser; Ira Schwartz; Dale S Martin; Mario T Philipp
Journal:  Clin Vaccine Immunol       Date:  2006-11-15

Review 7.  Diagnosis of lyme borreliosis.

Authors:  Maria E Aguero-Rosenfeld; Guiqing Wang; Ira Schwartz; Gary P Wormser
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

8.  Antibody profiling of Borrelia burgdorferi infection in horses.

Authors:  Peter D Burbelo; Kathleen E Bren; Kathryn H Ching; Adam Coleman; Xiuli Yang; Toru Kariu; Michael J Iadarola; Utpal Pal
Journal:  Clin Vaccine Immunol       Date:  2011-07-20

9.  BBK07, a dominant in vivo antigen of Borrelia burgdorferi, is a potential marker for serodiagnosis of Lyme disease.

Authors:  Adam S Coleman; Utpal Pal
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

10.  Simple objective detection of human lyme disease infection using immuno-PCR and a single recombinant hybrid antigen.

Authors:  Micah D Halpern; Claudia R Molins; Martin Schriefer; Mollie W Jewett
Journal:  Clin Vaccine Immunol       Date:  2014-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.